Repro Med Financials
KRMD Stock | USD 3.66 0.14 3.98% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Debt Equity Ratio | 0.0162 | 0.0154 |
|
| |||||
Current Ratio | 3.68 | 4.5475 |
|
|
The financial analysis of Repro Med is a critical element in measuring its lifeblood. Investors should not minimize Repro Med's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income |
|
Repro | Select Account or Indicator |
Understanding current and past Repro Med Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Repro Med's financial statements are interrelated, with each one affecting the others. For example, an increase in Repro Med's assets may result in an increase in income on the income statement.
Please note, the presentation of Repro Med's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Repro Med's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Repro Med's management manipulating its earnings.
Repro Med Stock Summary
Repro Med competes with Precision Optics,, InfuSystems Holdings, Utah Medical, Milestone Scientific, and Merit Medical. KORU Medical Systems, Inc. designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. KORU Medical Systems, Inc. was incorporated in 1980 and is headquartered in Chester, New York. Koru Medical operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 77 people.Specialization | Health Care, Health Care Equipment & Services |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US7599101026 |
CUSIP | 759910102 |
Location | New York; U.S.A |
Business Address | 100 Corporate Drive, |
Sector | Health Care Equipment & Supplies |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.korumedical.com |
Phone | 800 624 9600 |
Currency | USD - US Dollar |
Repro Med Key Financial Ratios
Return On Equity | -0.5 | ||||
Profit Margin | (0.38) % | ||||
Operating Margin | (0.14) % | ||||
Price To Sales | 5.24 X | ||||
Revenue | 28.52 M |
Repro Med Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 13.9M | 39.9M | 41.3M | 42.3M | 28.5M | 29.9M | |
Net Debt | (5.5M) | (27.1M) | (24.7M) | (12.5M) | (7.0M) | (6.7M) | |
Retained Earnings | 4.9M | 3.7M | (910.1K) | (9.6M) | (23.3M) | (22.1M) | |
Cash | 5.9M | 27.3M | 25.3M | 17.4M | 11.5M | 12.1M | |
Net Receivables | 3.2M | 2.6M | 4.3M | 4.5M | 4.1M | 4.3M | |
Inventory | 2.4M | 6.8M | 6.1M | 6.4M | 3.5M | 3.7M | |
Total Liab | 2.6M | 3.8M | 4.8M | 11.0M | 8.1M | 8.5M | |
Total Current Assets | 11.9M | 37.5M | 37.3M | 29.8M | 20.3M | 21.3M | |
Intangible Assets | 807.1K | 843.6K | 808.8K | 787.2K | 754.4K | 792.1K | |
Other Current Liab | 1.7M | 2.8M | 5.6M | 3.7M | 2.7M | 2.8M | |
Accounts Payable | 572.7K | 624.9K | 1.2M | 2.4M | 975.2K | 502.6K | |
Other Current Assets | 387.4K | 807.8K | 3.1M | 2.9M | 1.2M | 1.3M | |
Common Stock | 422.4K | 466.8K | 480.4K | 488.6K | 490.9K | 395.6K | |
Net Tangible Assets | 10.4M | 35.3M | 35.7M | 30.5M | 35.1M | 19.3M | |
Other Assets | 207.8K | 381.9K | 2.0M | 4.1M | 4.7M | 4.9M | |
Capital Surpluse | 6.3M | 35.9M | 40.8M | 44.3M | 50.9M | 53.4M | |
Net Invested Capital | 11.2M | 36.2M | 37.0M | 31.8M | 20.7M | 26.7M | |
Capital Stock | 422.4K | 466.8K | 480.4K | 488.6K | 490.9K | 505.7K | |
Net Working Capital | 9.5M | 33.9M | 32.5M | 22.8M | 15.8M | 22.4M |
Repro Med Key Income Statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Interest Expense | 6.7M | 4.8M | 637.2K | 145.6K | 167.4K | 159.1K | |
Total Revenue | 23.2M | 24.2M | 23.5M | 27.9M | 28.5M | 29.9M | |
Gross Profit | 14.9M | 14.9M | 13.8M | 15.4M | 16.7M | 17.5M | |
Operating Income | 585.7K | (1.3M) | (7.0M) | (10.8M) | (10.3M) | (9.8M) | |
Ebit | 7.4M | 1.2M | (7.0M) | (10.8M) | (10.3M) | (9.8M) | |
Research Development | 740.5K | 1.3M | 2.5M | 5.0M | 5.7M | 6.0M | |
Ebitda | 7.7M | 1.6M | (6.6M) | (10.2M) | (9.4M) | (8.9M) | |
Cost Of Revenue | 8.3M | 9.2M | 9.7M | 12.5M | 11.8M | 12.4M | |
Income Before Tax | 696.4K | (1.2M) | (6.4M) | (10.7M) | (9.8M) | (9.3M) | |
Net Income | 564.3K | (1.2M) | (4.6M) | (8.7M) | (13.7M) | (13.1M) | |
Income Tax Expense | 132.1K | 17.8K | (1.8M) | (2.0M) | 4.0M | 4.2M | |
Tax Provision | 132.1K | 17.8K | (1.8M) | (2.0M) | 4.0M | 4.2M | |
Interest Income | 80.7K | 42.4K | 13.1K | 145.6K | 561.3K | 589.4K | |
Net Interest Income | 80.7K | 42.4K | 13.1K | 145.6K | 561.3K | 589.4K |
Repro Med Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change To Inventory | (284.6K) | (4.4M) | 723.4K | (298.5K) | 2.9M | 3.1M | |
Change In Cash | 2.1M | 21.4M | (2.0M) | (7.9M) | (5.9M) | (5.6M) | |
Free Cash Flow | (104.9K) | (1.8M) | (4.7M) | (8.2M) | (5.7M) | (5.4M) | |
Depreciation | 340.2K | 418.6K | 463.1K | 587.1K | 870.4K | 913.9K | |
Capital Expenditures | 425.5K | 1.1M | 375.2K | 2.8M | 814.6K | 433.9K | |
Net Income | 564.3K | (1.2M) | (4.6M) | (8.7M) | (13.7M) | (13.1M) | |
End Period Cash Flow | 5.9M | 27.3M | 25.3M | 17.4M | 11.5M | 12.1M | |
Other Non Cash Items | (56.4K) | 1.3M | (1.0K) | 212.5K | 6.0M | 6.3M | |
Investments | 1.3M | (1.0M) | (366.2K) | (2.8M) | (814.6K) | (855.3K) | |
Change To Netincome | 961.6K | 3.0M | 890.6K | 1.1M | 1.2M | 882.4K |
Repro Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Repro Med's current stock value. Our valuation model uses many indicators to compare Repro Med value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Repro Med competition to find correlations between indicators driving Repro Med's intrinsic value. More Info.Repro Med Systems is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At present, Repro Med's Return On Equity is projected to slightly decrease based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Repro Med by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Repro Med Systems Systematic Risk
Repro Med's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Repro Med volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twelve with a total number of output elements of fourty-nine. The Beta measures systematic risk based on how returns on Repro Med Systems correlated with the market. If Beta is less than 0 Repro Med generally moves in the opposite direction as compared to the market. If Repro Med Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Repro Med Systems is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Repro Med is generally in the same direction as the market. If Beta > 1 Repro Med moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Repro Med Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Repro Med's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Repro Med growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Repro Med November 26, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Repro Med help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Repro Med Systems. We use our internally-developed statistical techniques to arrive at the intrinsic value of Repro Med Systems based on widely used predictive technical indicators. In general, we focus on analyzing Repro Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Repro Med's daily price indicators and compare them against related drivers.
Downside Deviation | 3.08 | |||
Information Ratio | 0.1813 | |||
Maximum Drawdown | 18.56 | |||
Value At Risk | (4.40) | |||
Potential Upside | 6.37 |
Complementary Tools for Repro Stock analysis
When running Repro Med's price analysis, check to measure Repro Med's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Repro Med is operating at the current time. Most of Repro Med's value examination focuses on studying past and present price action to predict the probability of Repro Med's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Repro Med's price. Additionally, you may evaluate how the addition of Repro Med to your portfolios can decrease your overall portfolio volatility.
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |